Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott

This article was originally published in The Gray Sheet

Executive Summary

FDA inspection of Murex' SUDS rapid HIV-1 test manufacturing was not related to the October closure of the Abbott subsidiary's Norcross, Georgia plant, the firm states. Although the firm planned to resume production in November (1"The Gray Sheet" Oct. 23, 2000, p. 24), it has not yet completed an investigation initiated after the test failed to meet internal specifications. An FDA inspection in August revealed QSR violations, including failure to submit information regarding tests affected by high background/false positive problems and failure to clarify steps that will be taken to investigate negative control and leaking bottle problems, according to a Dec. 15 FDA warning letter
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT014314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel